Skip to main content
    M

    MBX Biosciences, Inc. Common Stock (MBX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $53.12
    -2.82 (-5.04%)

    Market Cap: $2.78B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    MBX Biosciences, Inc. Common Stock (MBX) Competitors

    Updated Nov 17, 2026. Similar companies are ranked by business profile, size, sector and industry; metrics come from company filings and market prices.

    The companies most similar to MBX Biosciences, Inc. Common Stock are Legend Biotech (LEGN), Xencor (XNCR) and Beam Therapeutics (BEAM). By market cap, MBX Biosciences, Inc. Common Stock ranks 7th of the 13 companies on this page; Xenon Pharmaceuticals (XENE) is the largest at $3.98B.

    Peer Comparison

    MBX's revenue growth of 0.0% is in line with the peer median. Like the median peer, it pays no dividend.

    CompanyMarket capP/EP/SNet marginROICRev growthDiv yield
    MBX Biosciences, Inc. Common Stock (MBX)$2.78BN/AN/A0.0%N/A0.0%0.00%
    Legend Biotech Corp (LEGN)$3.39B266.5x2.3x-0.0%N/A32.0%0.00%
    Xencor Inc (XNCR)$2.78BN/A13.5x-58.8%-17.3%454.9%0.00%
    Beam Therapeutics Inc (BEAM)$2.36BN/A15.0x-73.9%-29.7%-96.8%0.00%
    Xenon Pharmaceuticals Inc (XENE)$3.98BN/AN/A0.0%N/A-100.0%0.00%
    Disc Medicine Inc. (IRON)$3.64BN/AN/A0.0%-40.0%0.0%0.00%
    Telix Pharmaceuticals Limited (TLX)$3.14BN/A5.3x3.8%-0.7%22.3%0.00%
    Zenas BioPharma, Inc. Common Stock (ZBIO)$1.90BN/A168.0x0.0%-104.3%-100.0%0.00%
    Harmony Biosciences Holdings (HRMY)$1.98B9.6x1.9x18.0%13.7%12.3%0.00%
    Dyne Therapeutics Inc (DYN)$3.22BN/AN/A0.0%-42.9%0.0%0.00%
    Arcus Biosciences Inc (RCUS)$2.51BN/A21.5x0.0%-75.9%-65.4%0.00%
    Celldex Therapeutics Inc (CLDX)$2.26BN/AN/A0.0%N/A-97.0%0.00%
    Replimune Group Inc (REPL)$2.08BN/AN/A0.0%-65.4%0.0%0.00%
    Peer median$2.65B138.0x13.5x0.0%-40.0%0.0%0.00%
    Market data as of Nov 17, 2026. Net margin covers the trailing 12 months, Rev growth compares the latest quarter with a year earlier and Div yield is the forward yield. P/E uses earnings per share for the last 12 months as companies report it, often adjusted, so it can show beside a negative net margin, which uses net income. P/E and P/S show N/A when those earnings or sales are negative or missing, or the multiple is above 1,000x.

    Similar Companies

    These are the 12 companies most similar to MBX Biosciences, Inc. Common Stock, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.

    CompanyAboutPeers
    Legend Biotech Corp (LEGN)
    Legend Biotech Corporation, a clinical-stage biopharmaceutical company, is dedicated to the discovery and development of new cell therapies for oncology...
    LEGN competitors
    Xencor Inc (XNCR)
    Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of cytokine and monoclonal antibody therapies designed...
    XNCR competitors
    Beam Therapeutics Inc (BEAM)
    Beam Therapeutics Inc., a biotechnology company, develops precision genetic drugs for patients with serious illnesses in the United States.
    BEAM competitors
    Xenon Pharmaceuticals Inc (XENE)
    Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, is dedicated to developing therapies to treat patients with neurological disorders...
    XENE competitors
    Disc Medicine Inc. (IRON)
    Disc Medicine, Inc., a clinical-stage biotechnology company, engages in discovery, development...
    IRON competitors
    Telix Pharmaceuticals Limited (TLX)
    Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic...
    Zenas BioPharma, Inc. Common Stock (ZBIO)
    Zenas BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of transformative immunology-based...
    ZBIO competitors
    Harmony Biosciences Holdings (HRMY)
    Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and markets therapies for patients with rare neurological disorders.
    HRMY competitors
    Dyne Therapeutics Inc (DYN)
    Dyne Therapeutics, Inc., a muscle disease company, is a biotechnology company focused on advancing therapeutics for genetically-derived muscle diseases...
    DYN competitors
    Arcus Biosciences Inc (RCUS)
    Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and markets cancer therapies in the United States.
    RCUS competitors
    Celldex Therapeutics Inc (CLDX)
    Celldex Therapeutics, Inc., a biopharmaceutical company, is dedicated to the development of therapeutic monoclonal and bispecific antibodies for the treatment...
    CLDX competitors
    Replimune Group Inc (REPL)
    Replimune Group, Inc., a biotechnology company, develops oncolytic immunogenic therapies to treat cancer. The company is headquartered in Woburn, Massachusetts.
    REPL competitors

    Frequently Asked Questions About MBX

    Who are MBX Biosciences, Inc. Common Stock's main competitors?

    The companies most similar to MBX Biosciences, Inc. Common Stock include Legend Biotech (LEGN), Xencor (XNCR), Beam Therapeutics (BEAM), Xenon Pharmaceuticals (XENE) and Disc Medicine (IRON), listed from the closest match.

    Who is MBX Biosciences, Inc. Common Stock's biggest competitor?

    Xenon Pharmaceuticals (XENE) is the largest of the similar companies at $3.98B; Legend Biotech (LEGN) is the closest match by business profile, size, sector and industry.

    How does MBX stock compare with its competitors?

    MBX's net margin is 0.0% against a peer median of 0.0%.

    Which of MBX Biosciences, Inc. Common Stock's competitors pays a higher dividend?

    MBX Biosciences, Inc. Common Stock pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.

    Is MBX Biosciences, Inc. Common Stock bigger than its competitors?

    No. MBX Biosciences, Inc. Common Stock is 7th by market cap among the 13 companies on this page; the largest is Xenon Pharmaceuticals (XENE) at $3.98B.